Annals of Nuclear Cardiology
Online ISSN : 2424-1741
Print ISSN : 2189-3926
ISSN-L : 2189-3926
Special Review Article
How Do We Establish Cardiac Sympathetic Nervous System Imaging with 123I-mIBG in Clinical Practice? Perspectives and Lessons from Japan and the US
Mark I. TravinIchiro MatsunariGregory S. ThomasKenichi NakajimaKeiichiro Yoshinaga
Author information
JOURNAL FREE ACCESS

2019 Volume 5 Issue 1 Pages 5-20

Details
Abstract

Cardiac denervation is associated with progressive left ventricular (LV) dysfunction, ventricular arrhythmias, and sudden cardiac death (SCD) in heart failure (HF). In this regard, it is important to evaluate cardiac-specific sympathetic nervous system (SNS) function. The radiotracer Iodine-123 meta-iodobenzylguanidine (123I-mIBG) can noninvasively evaluate presynaptic SNS function. Recent multicenter trials have shown 123I-mIBG to have strong predictive value for fatal arrhythmias and cardiac death in HF. 123I-mIBG was initially developed in the USA in the 1970s. In 1992, the Japanese Ministry of Health and Labour approved 123I-mIBG for the assessment of cardiac function. Following approval, the Japanese nuclear cardiology community developed 123I-mIBG imaging services in various medical centers. Japanese groups have been trying to establish the clinical utility of 123I-mIBG and standardize parameters for data acquisition and image analysis. The US Food and Drug Administration (FDA) has approved clinical use of 123I-mIBG for cardiac and non-cardiac imaging. However, clinical use of 123I-mIBG in the US has been very limited. The number of 1123I-mIBG studies in Japan has also been limited. There are similarities and differences between the two countries. To establish the clinical utility of 123I-mIBG in both countries, it is important to characterize the situations of 123I-mIBG in each.

Content from these authors
© 2018 Japanese Society of Nuclear Cardiology & American Society of Nuclear Cardiology
Previous article Next article
feedback
Top